Core Insights - Healthy Extracts Inc. has been invited to present at the ArcStone-Kingswood Growth Summit on September 18, 2025, in Toronto, Ontario [1] - The summit features over 20 high-growth companies and aims to facilitate strategic networking and insight-sharing among institutional and retail investors [1] Company Overview - Healthy Extracts Inc. operates as a platform focused on acquiring, developing, manufacturing, and marketing science-based nutraceuticals and oral delivery systems [1] - The company's products are targeted towards brain, heart, and metabolic health [1] Industry Context - The ArcStone-Kingswood Growth Summit 2025 is designed to connect high-growth companies with investors, highlighting the importance of networking in the nutraceuticals sector [1]

Group 1 - ProText Mobility, Inc. has had the "caveat emptor" designation removed and is now current in its corporate filing information, achieving OTCID Basic Market status [1] - The company specializes in the research, testing, and development of highly bioavailable botanical products using proprietary live plant extraction technology for nutraceutical and pharmaceutical applications [2]

Core Viewpoint - Gelteq Limited has successfully transitioned from research and development to active commercialization in the U.S. market through its collaboration with Healthy Extracts, marking a significant milestone for the company [2][3]. Company Overview - Gelteq Limited, headquartered in Melbourne, Australia, specializes in developing gel-based oral delivery solutions for various applications, including prescription drugs, nutraceuticals, pet care, and sports nutrition [4]. - The company's proprietary formulation technology addresses challenges in conventional drug delivery, such as taste masking, swallowing difficulties, and precision dosing [4]. Recent Developments - Healthy Extracts has launched products utilizing Gelteq's proprietary gel technology, which are the first to reach Gelteq's U.S. warehousing facility [2]. - The partnership with Healthy Extracts has evolved from initial warehousing and fulfillment arrangements to active sales and distribution, indicating growing momentum for Gelteq's gel delivery system [3]. Market Potential - The development highlights the growth potential of Gelteq's technology in large-scale wellness markets in the U.S. and its capability to meet consumer demand for innovative and clinically-informed products [2]. - The collaboration is expected to pave the way for additional products and partnerships in the U.S. market, enhancing Gelteq's presence and opportunities [3].

Core Insights - Jiva Technologies Inc. reported significant financial improvement for the fiscal year ended March 31, 2025, with revenue of CAD 4,600,991 and a reduced net loss of CAD 651,981 compared to a net loss of CAD 3,303,242 in the previous year [2][3] - The company has implemented a disciplined approach to cost management, resulting in substantial reductions in various expenses, which has positively impacted its financial performance [3][8] Financial Performance - Revenue for the year ended March 31, 2025, was CAD 4,600,991, with a net loss of CAD 651,981, a significant improvement from the previous year's loss of CAD 3,303,242 [2] - Loss per share improved to CAD 0.45 from CAD 3.99 in fiscal 2024, indicating a narrowing of losses [2] - Operating cash flow improved to CAD (873,632) from CAD (1,079,014) in 2024, showcasing better working capital management [8] Cost Management - Advertising and promotion expenses decreased by 84% compared to 2024, reflecting a shift to more cost-efficient marketing channels [8] - Consulting, legal, and salary expenses also saw significant declines, contributing to the overall reduction in operational costs [8] Strategic Positioning - Jiva Technologies is well-positioned for growth in the wellness technology sector, leveraging its unique platform that combines e-commerce technology, immersive wellness environments, and digital communities [6][7] - The company is actively pursuing joint ventures to enhance its online presence and support wellness brands, including a recent partnership with LIV3 for SugarShield [9] Operational Highlights - The company achieved a gross margin of 64% in Q1 2025, consistent with the previous quarter [8] - Operating income for 2025 was CAD 170,000 compared to an operating loss of CAD 278,000 in 2024, driven by lower operating expenses [8] - As of June 30, 2025, the cash balance was CAD 196,000, indicating a strengthened financial position [8]

Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and focuses on the R&D of novel patented nutraceuticals and innovative OTC products [6] Recent Developments - Cosmos Health's subsidiary, Sky Pharm SA, signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman [1][3] - Scientific Pharmacy is a leading healthcare and beauty company in Oman, known for its strong customer focus and international brand partnerships [2] - The agreement includes an initial purchase order of 42,000 units, with Scientific Pharmacy managing all core activities related to the distribution and marketing of the products [3] Market Insights - The GCC nutraceuticals market was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033, with a compound annual growth rate (CAGR) of 8.7% [4] - Growth in the nutraceuticals market is driven by rising health awareness, higher disposable incomes, government initiatives addressing lifestyle diseases, rapid urbanization, and the expansion of retail and e-commerce channels [4] Strategic Outlook - The CEO of Cosmos Health expressed excitement about the expansion into Oman, highlighting the potential for significant revenue generation supported by Scientific Pharmacy's established network [5] - The agreement is seen as a milestone that showcases the quality of Cosmos Health's products and the increasing global demand for the Sky Premium Life brand [5]

BioHarvest Sciences (NasdaqGM:BHST) Update Summary Company Overview - **Company**: BioHarvest Sciences Inc. - **Industry**: Biotechnology focusing on health and wellness through plant-based compounds Key Points and Arguments Business Strategy and Vision - The company's North Star is to discover, develop, manufacture, and democratize life-changing compounds from plants for health and wellness while preserving the planet [2][3] - BioHarvest operates two major business units: a direct-to-consumer health and wellness unit and a Contract Development and Manufacturing Organization (CDMO) services unit [3][4] Financial Performance - Since launching in the U.S. in May 2021, the direct-to-consumer unit has generated over $60 million in revenue from VINIA dietary supplements, with the last quarter reporting $8.5 million in revenue and a 60% gross profit margin [3][4] Technological Advancements - The company has developed the capability to produce plant exosomes, which are nanosized extracellular vesicles that enhance intercellular communication and have significant health benefits [6][7] - Plant exosomes can penetrate human cells effectively, offering antioxidant, anti-inflammatory, anti-aging, and antimicrobial properties [7][8] Competitive Advantage - BioHarvest's bioreactors allow for controlled, consistent, and scalable production of plant exosomes, overcoming limitations of traditional plant-derived exosome production [8][10] - The unique production process results in high-quality, homogeneous exosomes that are not available from other sources [12][13] Market Opportunities - The company aims to disrupt the $14 billion U.S. cosmetics industry and the $18 billion electrolyte beverage market with its innovative products [14][18] - The hydration category is particularly targeted, with a focus on improving blood flow and hydration through a new electrolyte drink powered by their proprietary formulation [21][22] HealthPros Affiliate System - BioHarvest is building a network of HealthPro affiliates, including health professionals and fitness experts, to promote its products and expand market reach [31][32] - The launch of the hydration product is planned for November 15, aligning with Black Friday promotions [30] Future Outlook - The company anticipates achieving adjusted EBITDA profitability by the fourth quarter of 2025 [36][84] - There are ongoing discussions with potential CDMO customers across various industries, including cosmetics and pharmaceuticals, to leverage the new exosome technology [50][52] Intellectual Property - BioHarvest has filed provisional patents to protect its innovative exosome production technology, ensuring a competitive edge in the market [64][66] Additional Important Information - The company emphasizes the importance of hydration for overall health, with 64% of global consumers recognizing its significance [19] - The hydration product will utilize naturally sourced electrolytes and is designed to meet the needs of various consumer segments, from athletes to seniors [27][29] This summary encapsulates the key insights from the BioHarvest Sciences update, highlighting the company's strategic direction, technological advancements, market opportunities, and future growth potential.

Core Insights - HBC has appointed Paul Bruhn as Head of New Business Development, bringing over 25 years of experience in healthcare and medical nutrition [1][2] - The company has developed a unique portfolio of bioactive ingredients derived from salmon, including OmeGo®, ProGo®, NT-II™, and PetGo®, which are scientifically backed and sustainable [3][4] - HBC emphasizes scientific evidence in its product development, leading to academic partnerships and the identification of unique health benefits [5][6] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, upcycling side streams of the salmon industry [3][6] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [7] Product Portfolio - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [4][5] - OmeGo® is noted for its full spectrum of Omega fatty acids, being 100% natural and clinically proven for various health benefits [3][5] Market Focus - HBC aims to address market needs for clinically backed nutrition sources, particularly in Asia, China, and the ANZ region [2][3] - The company is exploring potential therapeutics through its biotech-focused spin-off, HBC Immunology, targeting prostate and ovarian cancer, as well as asthma treatments [6]

Core Insights - Calcium is essential for maintaining bone health, yet insufficient dietary intake and low absorption efficiency are common issues. Proper calcium supplementation involves selecting the right type of calcium, accompanying nutrients, and dosage forms to enhance effectiveness [1] Product Summaries Calcium Tablets - **Caltrate Calcium D3 Tablets**: Contains 600mg of calcium carbonate and 125 IU of vitamin D3. It utilizes micro-pulverization technology to enhance dissolution speed and absorption rate. The addition of imported vitamin D helps in preventing osteoporosis [4] - **Swisse Calcium Citrate Tablets**: Comprises 333mg of calcium citrate, 665 IU of vitamin D, and 60μg of vitamin K. It is gentle on the gastrointestinal tract, dissolves quickly in water, and helps avoid gastrointestinal discomfort while promoting calcium deposition in bones [8] Calcium Capsules - **By-Health DK Calcium Capsules**: Contains 500mg of calcium carbonate, 360 IU of vitamin D, and 24μg of vitamin K. It features a three-in-one formula that aids in calcium absorption and deposition in bones [11] - **Schiff Vitamin D and K Softgels**: Composed of 500mg of calcium (both carbonate and citrate), 360 IU of vitamin D, and 24μg of vitamin K. It promotes calcium absorption in the intestines and its deposition in bones [15] Liquid Calcium - **Mom's Garden Liquid Calcium**: Contains 500mg of patented organic calcium (salmon bone calcium and calcium citrate), 400 IU of vitamin D, and 30μg of vitamin K. It boasts a six-fold absorption rate compared to other calcium types and includes collagen for joint repair [18] - **Caltrate Liquid Calcium**: Comprises 300mg of calcium citrate, 30mg of casein phosphopeptide (CPP), 2.3mg of zinc, 5μg of vitamin D, and 22.5μg of vitamin K. It enhances calcium absorption and prevents sedimentation [21] Recommendations - For individuals with sensitive stomachs, calcium citrate or organic calcium options are recommended, particularly liquid forms [22] - For optimal absorption and comprehensive bone nutrition, products containing vitamin D3, K2, collagen, or CPP are advisable [22] - For those without constipation issues seeking cost-effectiveness, traditional calcium carbonate products are a reliable choice [22]

Core Insights - BioHarvest Sciences reported a robust 41% year-over-year revenue growth for Q2 2025, reaching $8.5 million, driven by strong sales in its core VINIA® capsule business and new product launches [4][6] - The company aims to achieve adjusted EBITDA breakeven by Q4 2025, supported by continued growth in its product lines and a strong CDMO pipeline [3][4] Financial Performance - Total revenues for Q2 2025 increased to $8.5 million from $6.0 million in Q2 2024, with gross margins expanding by 800 basis points to 60% [4][6] - Gross profit rose 65% to $5.1 million, attributed to increased manufacturing scale and improved yields [7] - Operating expenses increased to $6.9 million from $4.8 million year-over-year, primarily due to higher marketing spend and costs associated with the CDMO services division [8] Net Loss and Cash Position - The net loss for Q2 2025 was $4.0 million, or $0.24 per share, compared to a net loss of $0.7 million, or $0.04 per share, in Q2 2024 [9] - Cash and cash equivalents as of June 30, 2025, totaled $3.7 million, up from $2.4 million at the end of 2024 [10] Product and Market Developments - The company has launched new products, including VINIA® Daily Chews 2X Formula, and secured a new CDMO contract for developing a plant-based fragrance compound [4][13] - Management expects to launch additional products and CDMO services in the second half of 2025, including an electrolyte drink targeting the $13 billion hydration market [4][13] Strategic Initiatives - BioHarvest is focusing on three growth initiatives: expanding its Health Pros affiliate program, launching a new electrolyte drink, and introducing an AI-enabled CDMO discovery phase [13] - The company continues to position its botanical synthesis technology as a commercial engine for high-value plant-based compounds [5]

Core Viewpoint - The global fish oil EPA and DHA market is projected to reach $2.02 billion by 2031, with a compound annual growth rate (CAGR) of 3.4% in the coming years [1]. Market Overview - The fish oil DHA segment dominates the market, accounting for approximately 76.8% of the total market share [8]. - Dietary supplements represent the largest downstream market for fish oil EPA and DHA, holding about 52.2% of the market share [10]. Key Drivers - The increasing burden of chronic diseases is driving demand for preventive nutrition, with EPA known for its anti-inflammatory properties and DHA for its role in brain development [15]. - Growing awareness of cognitive and brain health is accelerating the demand for DHA, particularly in prenatal supplements and infant formula [15]. - The expanding middle class and health-conscious consumers in emerging markets, especially in the Asia-Pacific region, are shifting towards preventive self-care, viewing fish oil supplements as affordable health investments [15]. - The trend towards functional foods is broadening application scenarios, with EPA and DHA being added to various food products, enhancing their market reach [16]. - The adoption of pharmaceutical-grade EPA is enhancing clinical value, with regulatory recognition boosting the omega-3 industry's growth in healthcare [16]. - Advances in purification technologies have improved product quality and consumer trust, addressing previous concerns about taste and contamination [16]. Major Obstacles - Fluctuations in raw material availability and sustainability pressures are significant challenges, as fish oil production relies heavily on wild-caught fish species [17]. - Regulatory complexities and inconsistencies across regions complicate compliance and increase operational costs for EPA and DHA products [17]. - Consumer skepticism due to concerns over contamination and product efficacy is undermining trust in the market [17]. - Competition from alternative sources of omega-3, such as plant-based options and krill oil, is growing, particularly among environmentally conscious consumers [17]. Key Players - Major global manufacturers of fish oil EPA and DHA include KD Pharma, Croda, BASF, and others, with the top ten companies holding about 64.0% of the market share [6].